Three-dimensional structure of a Nanobody® (modeled on the VHH with pdb-code 1U0Q, Cambillau et al). The target molecule is recognized by the surface formed by three hypervariable regions located at the top of the molecule (in green, cyan and blue). Hallmarks, amino acid residues that further differentiate a camelid VHH from a human VH, can be located at different positions within the framework regions, and here are coloured red, pink and magenta.

Home News room Press releases
Press Releases

2007

 

25/09/2007

ablynx is awarded eur 1.9 million grant to explore new therapeutic uses of nanobodies®

nl

07/09/2007

Ablynx and boehringer ingelheim announce major global strategic alliance to discover, develop and commercialise novel nanobody® therapeutics

NL

06/08/2007

Ablynx strengthens management team with the appointment of dr josefin-beate holz as chief medical officer

NL     fr  

02/07/2007

Ablynx announces interim results of first nanobody® phase i study of alx-0081 (ANTI-VWF)                                  

NL     fr  

18/06/2007
Ablynx identifies novel Nanobodies® achieving SECOND milestone in Procter & Gamble collaboration 

NL     fr

08/01/2007
Ablynx and Boehringer Ingelheim sign us$265M research and licensing agreement to develop new Alzheimer's treatments

NL      fr  

 

News archive